Month: <span>July 2021</span>

Home / 2021 / July
Real-time stress detection devices could help fight alcohol relapses
Post

Real-time stress detection devices could help fight alcohol relapses

WASHINGTON STATE UNIVERSITY IMAGE: MICHAEL CLEVELAND WEARS THE EMPACTA E4 WRIST DEVICE USED IN THE STUDY TO MEASURE REAL-WORLD STRESS ON PARTICIPANTS. CREDIT: CLARA HILL, WASHINGTON STATE UNIVERSITY Wearable devices can detect people’s stress, according to new Washington State University research, opening potential new interventions for people with addictions.  In a paper published today, July...

Post

Three in ten Americans increased supplement use since onset of pandemic

THE REIS GROUP WASHINGTON (July 21, 2021) – Twenty-nine percent of Americans are taking more supplements today than they were before the COVID-19 pandemic, bringing the percentage of U.S. supplement-takers to 76%, according to a new survey conducted by The Harris Poll on behalf of Samueli Foundation. Nearly two-thirds of those who increased supplement use...

Post

The need for nuance in carbohydrate recommendations

FOODMINDS Carbohydrates have traditionally been the largest source of energy intake for much of the world’s population1. However, without a standard definition for carbohydrate quality, some foods that contain carbohydrates are often stigmatized based on isolated and reductionist assessment methods that fail to consider their contributions to nutrient intakes and balanced, healthy diets. A new...

Pandemic-based approach to methadone treatment restrictions should remain
Post

Pandemic-based approach to methadone treatment restrictions should remain

by Matthew Kristoffersen,  Yale University Methadone. Abulic Monkey. Credit: CC2.0 By: Abulic Monkey When the COVID-19 pandemic ripped through New England and the rest of the United States in early 2020, substance use disorder treatment centers were forced to make massive changes to minimize the spread of coronavirus. The fear of COVID-19 spread into crowded treatment programs...

Rates of adverse events lower with apixaban for A-fib in older adults
Post

Rates of adverse events lower with apixaban for A-fib in older adults

(HealthDay)—For older adults with atrial fibrillation, apixaban is associated with lower rates of adverse events than warfarin across all frailty levels, according to a study published online July 20 in the Annals of Internal Medicine. Dae Hyun Kim, M.D., M.P.H., Sc.D., from Harvard Medical School in Boston, and colleagues examined outcomes for Medicare beneficiaries with atrial...

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection
Post

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

By Sally Robertson, B.Sc. Jul 19, 2021 Researchers in Finland have conducted a study showing that the neutralizing antibodies generated following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – generally persist for at least a year. “Studies of individuals who have recovered from natural...

UK opts not to vaccinate most under-18s against COVID-19
Post

UK opts not to vaccinate most under-18s against COVID-19

by Danica Kirka  People enjoy the weather on Bournemouth beach in Dorset, England, Monday, July 19, 2021. Credit: Steve Parsons/PA via AP The British government has decided not to inoculate most children and teenagers against COVID-19 until more data on the available vaccines becomes available. Children as young as 12 with severe neuro-disabilities, Down syndrome,...

Post

FDA supports limited distribution of antismoking drug Chantix despite carcinogen risk

July 16, 2021, 05:13 PM Josh Sullivan Associate Editor Earlier this month, the FDA alerted the public that Pfizer had voluntarily recalled its stop-smoking drug Chantix after finding elevated levels of cancer-causing nitrosamines. Now, the FDA is permitting certain manufacturers to temporarily distribute the drug that has more than the usual nitrosamine, so long as...

New Treatment Option for Restless Legs?
Post

New Treatment Option for Restless Legs?

Erik Greb July 20, 2021 The antiplatelet medication dipyridamole reduces motor and sensory symptoms of restless legs syndrome (RLS) and improves sleep duration for treatment-naive patients, results of a small, randomized, placebo-controlled trial show. After 2 weeks of treatment, scores on the International Restless Legs Rating Scale (IRLS) decreased by 13 points for patients who received dipyridamole, compared with 5 points among those...

Preclinical study finds success in reversing age-related memory loss
Post

Preclinical study finds success in reversing age-related memory loss

By Rich Haridy July 22, 2021 New research is focussing on modifying structures in the brain known as perineuronal nets to mitigate age-related memory declineSpectral/Depositphotos An intriguing new study from researchers in the United Kingdom is proposing an innovative method to treat age-related memory loss. The preclinical research shows memory decline in aging mice can be reversed by manipulating...